Regulus Therapeutics (RGLS) Tops Q3 EPS by 3c

November 1, 2016 4:11 PM EDT
Get Alerts RGLS Hot Sheet
Trade RGLS Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.37), $0.03 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $1.2 million.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment